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Background: Primary meningeal melanocytoma is a rare neurological disorder. Although it may occur at the base
of the brain, it is extremely rare at the anterior cranial fossa.
Case presentation: A 27-year-old man presented with headache and diplopia at our department. Fundoscopy
showed left optic nerve atrophy and right papilledema consistent with Foster-Kennedy syndrome. Neurological
exams were otherwise normal. A left frontal irregular space-occupying lesion was seen on magnetic resonance
imaging (MRI), and enhancement was shown on contrast-enhanced computed tomography (CT) scan. CT
angiography (CTA) revealed vascular compression around the lesion. Prior to surgery, meningioma was diagnosed
and gross tumor removal was performed. On postoperative pathohistological exam, the tumor proved to be a
meningeal melanocytoma, WHO grade I. No skin melanoma was found. After surgery, the patient received radiation
therapy. No tumor was seen on follow-up MR images six months after surgery. The patient was well after two and a
half years, and there was no tumor recurrence on the follow-up CT.
Conclusions: This case of primary meningeal melanocytoma located at the anterior cranial fossa is very rare.
Although primary meningeal melanocytoma is benign, it may behave aggressively. Complete surgical resection is
curative for most cases. Radiation therapy is important to prevent relapse of the tumor, especially in cases of
incomplete surgical resection.Background
Primary meningeal melanocytoma is a benign central
nervous system (CNS) neoplasm rarely seen by neuro-
surgeons in clinical practice. The tumor is derived from
melanocytes, and was first reported by Limas and collea-
gues in 1972 [1]. Although prognosis is good, there have
been accounts of aggressive behavior and frequent re-
lapse [2-7]. Because primary meningeal melanocytoma is
rarely located at the anterior cranial fossa, it can be easily
misdiagnosed before surgery [8,9]. Here we report a rare
case of primary meningeal melanocytoma located at the
anterior cranial fossa. The relevant medical literature is
reviewed.* Correspondence: jinluyu@hotmail.com
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reproduction in any medium, provided the orCase presentation
A 27-year-old man presented with headache and diplopia
for three days. The headache was a dull pain not accom-
panied by vomiting or dizziness. Fundoscopy showed left
optic nerve atrophy and right papilledema, consistent
with Foster-Kennedy syndrome. Neurological examina-
tions were otherwise normal, and laboratory results were
unremarkable.
A left frontal irregular space-occupying lesion was seen
on magnetic resonance imaging (MRI), and enhancement
was shown on contrast-enhanced scan. The lesion ap-
peared hyperintense on T1-weighted images. Hypoin-
tense signals were noted on T2-weighted images. The
tumor was primarily located at the frontal lobe with ven-
tricular compression and midline shift (Figure 1). Brain
CT angiography (CTA) showed compression of the anter-
ior and middle cerebral arteries. Small branches from theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Preoperative MR images showing the left frontal tumor with lobulation, ventricle compression and midline shift. A: Axial view.
The lesion appears hyperintense on T1-weighted images. B: Axial view. Hypointense signals are noted on T2-weighted image of the brain. C: Axial
post contrast T1-weighted view. Contrast enhancement of the tumor. D: Sagittal view. Adhesion of the tumor to the meninges of the anterior
cranial fossa (arrow) MR, magnetic resonance.
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the tumor (Figure 2). Meningioma was diagnosed prior to
surgery.
Surgery was performed via the left frontotemporopar-
ietal approach and the tumor was removed four days
after admission. The tumor was located at the anterior
cranial fossa and adhered closely to the dura of the skull
base. Only the infiltrated dura was not removed; the
resection was Simpson’s grade II (that is, complete
removal + coagulation of dural attachment). Grossly, the
tumor was a soft, well-circumscribed pigmented lesion
with a capsule, and proved to be meningeal melano-
cytoma on histopathological examination of resected
tissues.
Immunohistochemistry was positive for the melanocy-
tic features human melanoma black (HMB)-45, vimentin
and S-100 protein, while epithelial membrane antigen
(EMA), creatine kinase (CK) and progesterone receptor
(PR) were negative. Cellular proliferation was assessed
via staining for Ki-67. Ki-67 was positive, but less than
1% (Figure 3). Based on the pathology results, the tumor
was adjudged World Health Organization (WHO) grade
I (low grade). After the diagnosis was established, adetailed physical examination was performed in which
no skin melanoma was found. The patient denied a his-
tory of melanocytoma.
The patient received one-time 30 Gray radiation ther-
apy after surgery and the duration was one day. No
tumor relapse was seen on follow-up MRI six months
after surgery (Figure 4). At follow-up two and a half
years after surgery, the patient was free of symptoms and
no tumor recurrence was shown on the CT scan.
Discussion
Primary meningeal melanocytoma is a benign tumor of
the CNS. The annual incidence is about 1 person per 10
million [4]. The diagnosis of primary meningeal melano-
cytoma is mainly based on histopathological findings.
The CNS melanocytoma may be diffuse melanosis, men-
ingeal melanocytoma or primary malignant melanoma
[4,10,11]. Limas and Tio [1] first described meningeal
melanocytoma in 1972. Although the exact cause of the
disease remains unclear, meningeal melanocytomas are
thought to arise from normally occurring leptomeningeal
melanocytes. Recent embryological studies suggest that
melanocytes originate from the neural crest of the
AB C
Figure 2 CTA of the brain showing the association of the tumor with adjacent vascular structures. A: Axial computed tomography
angiography (CTA). The tumor compressed the ipsilateral anterior and middle cerebral artery (arrows). B-C: CTA image. The tumor was fed by
branching arteries from the middle and anterior cerebral arteries.
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areas commonly involved are the base of the brain, the
cerebellopontine angle and the pineal body [2-4,12]. In
rare cases, intrathecal meningeal melanocytoma has also
been reported [7,13].
Although primary meningeal melanocytoma may occur
at the base of the brain, the anterior cranial fossa is an
extremely rare location, and only a few similar cases have
been reported [8,9]. Kawaguchi et al. [8] in 1998
described a patient with a meningeal melanocytoma
located in the left frontal region, but the tumor was not
connected to the skull base [8]. In 2003, Uozumi et al. [9]
reported a patient with a recurrent meningeal melanocy-
toma located in the left frontal region. Although the
tumor was connected with the anterior cranial fossa, it
was not as big as our case. Hino et al. [14] reported a pa-
tient with a combination of nevus of Ota and meningeal
melanocytoma. While the tumor involved the anterior
cranial fossa, it originated from the sphenoid wing and
superior orbital fissure. When primary meningeal mela-
nocytomas occur in unusual locations, from imaging
examinations they were often confused with meningioma
[15]. Therefore, our case is reported herein so that it can
be known that primary meningeal melanocytoma may
occur in such an unusual area.Patients with meningeal melanocytoma may present
with a variety of neurological symptoms, including in-
creased intracranial pressure, neuropsychiatric symptoms,
seizures and (rarely) spinal cord compression [5-7]. Our
patient presented with headache and eye symptoms that
were consistent with Foster-Kennedy syndrome, but are
inconsistent with anterior cranial fossa lesions.
In general, the preoperative diagnosis of meningeal
melanocytoma is often difficult, as the clinical and neu-
roradiological features of the tumor are not definitive.
However, these features have been described previously.
The tumor appears hyper- or iso-intense on CT scan with
contrast enhancement, and presents with a high signal on
T1- and fluid attenuated inversion recovery (FLAIR), and
a low signal on T2-weighted MRI with contrast-
enhancement [3,16].
It is extremely difficult to differentiate primary malig-
nant melanocytoma from meningeal melanocytoma on
MRI, because both tumors consist histologically of mel-
anin pigments [17]. Thus, in the present case, our patient
was initially diagnosed with meningioma. On retrospec-
tive review of the MR images, the diagnosis of meningeal
melanocytoma was established.
In previous studies of meningeal melanocytoma using




Figure 3 Histopathological characteristics of the tumor. A: Melanin pigment is abundant and the cells are arranged in bundles with
prominent nuclei. (H&E, 200×). B: HMB-45 (+) staining of tumor cells. C: Vimentin (+) staining of tumor cells. D: S-100 (+) staining of tumor cells. E:
Ki-67(+), less than 1%.
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study, CTA was performed to clarify the anatomical asso-
ciation between the meningeal melanocytoma and adja-
cent vessels. CTA has both advantages and disadvantages
for the evaluation of meningeal melanocytoma located at
the anterior cranial fossa. CTA can quickly provide a 3D-
image of the tumor and intracranial main arteries, includ-
ing the tumor stains, in a minimally invasive manner.
From the CTA the neurosurgeon can determine the ana-
tomical associations between the tumor and important
structures, which is helpful for designing the approach.
However, CTA cannot provide information regarding dy-
namic artery flow. Because the contrast is supplied by
veins, the CT angiogram is a complex imaging of the in-
ternal and external carotid arteries, which is not selective,
and it is sometimes very difficult to find the exact blood
supply arteries [18,19]. In our study we found that thetumor compressed the ipsilateral anterior and middle
cerebral artery and was supplied by branching arteries
from the middle cerebral artery and anterior cerebral ar-
tery. Because of this limitation of CTA, we could not de-
termine whether the dura provided the blood supply to
the tumor because the meningeal melanocytoma closely
adhered to the dura. We believe that meningeal vessels
also provided the blood supply. Even with this disadvan-
tage, however, CTA has great value in the preoperative
evaluation of the relatedness of the tumor and adjacent
vessels.
The histopathological characteristics of meningeal
melanocytoma have been reported elsewhere in the
medical literature [20-22]. Grossly, the tumor usually
appears as a black lesion that is firmly attached to the
underlying meninges. Microscopically, melanin granules
are commonly seen. Immunohistochemically, meningeal
A B
Figure 4 Follow-up MRI scan at six months. Axial (A) and coronal (B) MR images show no residual tumor tissues or tumor relapse in the left
frontal lobe.
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and vimentin [2-4]. Keratin, EMA and glial fibrillary
acidic protein (GFAP) are usually negative; positive
HMB-45 and negative EMA are strongly suggestive
[20,21]. In our case, we found that the tumor was abun-
dant with melanin and the cells were arranged in bun-
dles with prominent nuclei. Immunohistochemistry was
positive for HMB-45, vimentin and S-100, and negative
for EMA, CK and PR. These findings are consistent with
the known pathological and immunohistochemical char-
acteristics of the tumor.
Although meningeal melanocytoma is benign, relapse
and malignant transition have been reported. Wang and
colleagues [6] reported a case of primary meningeal mel-
anocytoma located at the temporal lobe, in which malig-
nant transition was confirmed histopathologically three
years after resection of the tumor. Similar cases of malig-
nant transition were reported in patients with spinal
meningeal melanocytomas [7]. In 2003, Uozumi et al. [9]
reported a patient who was given a gross total removal,
but after four years the meningeal melanocytoma re-
curred and the patient underwent radiotherapy and an
additional operation. Histopathological examination
revealed a malignant melanoma originating from a mela-
nocytoma [9]. In 2004, Roser et al. [23] reported a patient
who had undergone a subtotal removal and subsequently
a second operation. Pathology revealed a malignant mel-
anoma originating from a melanocytoma. After the sec-
ond operation the patient died from the rapid spread of
the malignant melanoma. Despite its benign appearance,
meningeal melanocytoma may follow an aggressive
course, with recurrence possible from seven months to
five years after complete excision [24,25].Because meningeal melanocytoma may transform into
malignant melanoma, complete resection if possible is
advised. Complete surgical resection of the tumor is the
standard treatment for this disease, but many factors can
influence the success of total removal, the most import-
ant being tumor location. Like meningiomas, when men-
ingeal melanocytomas closely adhere to the dura of the
skull base it is very difficult to remove the infiltrated
dura altogether, so only Simpson’s grade II can be
achieved [26]. For these tumors, radiotherapy is neces-
sary, but for those tumors given complete removal there
is still debate whether radiotherapy is necessary.
There have been reports of tumor recurrence even
after complete excision. Therefore, adjuvant radiation
therapy is advised in cases of both complete and in-
complete resection [4,27]. However, in 2004 Rades and
colleagues [25] published a retrospective review that
investigated the five-year survival rate of meningeal mel-
anocytoma in 89 cases. The five-year-survival rate was
100% in patients who had received complete resection,
but only 46% in those whose resection was incomplete.
Interestingly, the survival rate was 100% in patients with
combined incomplete resection and adjunct radiation
therapy. Based on the data concerning relevant cases
available from the literature, complete tumor resection
should be considered the best therapeutic option. In
cases in which complete resection is not possible, post-
operative radiation seems to be of benefit, as well as
incomplete resection combined with postoperative radio-
therapy. Up to the present time, this is the biggest and
most convincing study [25].
In the present case, the meningeal melanocytoma was
located at the anterior cranial fossa, and the tumor
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dura was only given coagulation and not removal, so in
fact this operation was a gross total removal, and
belonged to Simpson’s grade II. Based on the results of
Rades et al. [25] described above, our patient was admi-
nistered radiation therapy after surgical resection, and
showed good prognosis at two and a half years.
The necessity for radiotherapy depends on the degree
of proliferation of the meningeal melanocytoma [24,25].
The antigen Ki-67 is a cellular marker for proliferation,
and staining for Ki-67 will reveal the growth fraction of a
cell population. In Roser et al.’s report [23] described
above, the meningeal melanocytoma was subtotally
resected, the level of proliferation was low, and only 3%
of cells were stained with Ki-67. The patient did not re-
ceive radiotherapy and after 12 years the tumor recurred
and had a malignant transformation. At the time of re-
currence, 5% of cells stained positive for Ki-67 [23].
Thus, the slow growth of the meningeal melanocytoma
makes low Ki-67 staining relevant. If the tumor had been
completely resected or radiotherapy administered, the
patient’s prognosis might have been excellent. Navas
et al. [28] also recommended the MIB-1 (mindbomb E3
ubiquitin protein ligase 1)/Ki-67 labeling index, for its
potential prognostic value in predicting aggressive clin-
ical behavior and malignant progression of primary mel-
anocytic neoplasms of the CNS [28]. In our study, the
Ki-67 proliferative index was less than 1%. Although this
is very low, radiotherapy was required because of the
Simpson’s grade II removal.Conclusions
In summary, we report herein a rare case of primary
meningeal melanocytoma located at the anterior cranial
fossa. Although meningeal melanocytomas are benign
tumors, they may present with aggressive behaviors.
Complete surgical resection can be curative for most
cases. Radiation therapy is important to prevent relapse
of the tumor when complete surgical resection is not
possible.Consent
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